Research programme: CD26 antigen antagonists - DARA BioSciences

Drug Profile

Research programme: CD26 antigen antagonists - DARA BioSciences

Alternative Names: DB 040; DB 160; DB 295; Dipeptidyl peptidase IV inhibitors; DPP-IV inhibitors

Latest Information Update: 17 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DARA Biosciences
  • Developer Midatech Pharma US
  • Class Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Feb 2012 Research programme: CD26 antigen antagonists - DARA BioSciences is available for licensing as of 15 Feb 2012. http://www.darabio.com
  • 17 Jan 2012 DARA BioSciences has identified DB 160 as a preclinical candidate for future development and monetisation
  • 02 Aug 2007 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top